French HIV Experts on Early Antiretroviral Treatment for Prevention: Uncertainty and Heterogeneity

Early use of highly active antiretroviral treatment (ART) in people living with HIV for HIV prevention has gained legitimacy but remains controversial. Nineteen French HIV experts with diverse specializations (over half of whom were clinicians) were qualitatively interviewed on their views about ART irrespective of CD4 count of more than 500 cells/mm3 for purposes of HIV prevention, which is not systematically recommended in France. Content analysis identified 2 broad categories: individual considerations (subcategories: patient health and well-being; patient preparedness and choice) and collective considerations (subcategories: HIV transmission risk; impact on the epidemic; cost). Uncertainty surrounded many experts’ considerations, and unity was lacking on key issues (eg, candidacy for early preventive treatment, expected clinical- and population-level effects). An umbrella theme labeled "Weighing the merits of early ART in the face of uncertainties" was identified. Our analyses raise doubts about the current acceptability of widespread implementation of early ART for HIV prevention in France.
Source: Journal of the International Association of Physicians in AIDS Care (JIAPAC) - Category: Infectious Diseases Authors: Tags: Antiretroviral Therapy Source Type: research